Scopus Eşleşmesi Bulundu
13
Atıf
180
Cilt
Özet
Objective: Clozapine is one of the most effective drugs for resistant schizophrenia, but its severe metabolic and hematological side effects limit the use of clozapine. It has been reported that clozapine blood concentrations should be maintained between 350−600 ng/mL. Our aim was to develop a determination method for clozapine and its main metabolites norclozapine and clozapine-N-oxide, to perform validation studies and to investigate the change of various biochemical parameters in patients using clozapine. Methods: A liquid chromatography-tandem mass spectrometry (LC–MS/MS) method was developed and validated for clozapine measurement. Thus, blood samples were collected from 38 patients with schizophrenia and 32 healthy volunteers. Biochemical and hematological parameters were measured by Beckman-Coulter AU 5800 (Beckman Coulter, Brea, USA) and Beckman Coulter LH 780 analyzer (Beckman Coulter, Miami, FL, USA), respectively. Hormone levels were analyzed using Cobas 6000 analyzer (Roche Diagnostics, Germany). Results: The LC[sbnd]MS/MS method was linear between 1.22−2500 ng/mL (r2 = 0.9971) for clozapine. The retention times of clozapine, norclozapine and clozapine-N-oxide were 0.92, 0.89 and 0.95, respectively. Blood glucose (GLU) (p = 0.025), low density lipoprotein (LDL-cholesterol) (p = 0.015), triglyseride (TG) (p = 0.042) and total cholesterol (TC) (p = 0.024) levels were higher; hemoglobin (HGB) (0.015), mean corpuscular hemoglobin (MCH) (0.036), red blood cell count (RBC) (0.020), neutrophil (NEU) (0.034), and platelet (PLT) (P = 0.005) levels were lower in the clozapine group. Conclusions: This LC–MS/MS method was rapid, simple, cost-effective and suitable for the routine clozapine monitoring. Furthermore, norclozapine and clozapine-N-oxide were also determined. Monitoring of metabolic and hematological parameters with clozapine levels is very important. However, the limitations of the study were that the method was not validated for norclozapine and clozapine-N-oxide, so the validation parameters were not evaluated for these two metabolites.
Web of Science Eşleşmesi Bulundu
12
WoS Atıf
180
Cilt
Article
Belge Türü
Kaynak: JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Anahtar Kelimeler (WoS)
Havuzumuzdaki Atıflar 0
Bu makaleye, sistemimizdeki Scopus veritabanında bulunan 0 makale atıf yapmıştır. Scopus genel atıf sayısı: 13.
Bu makaleye, kendi Scopus havuzumuzdaki başka bir makaleden atıf kaydı bulunmuyor.
Scimago Dergi Bilgisi
Otomatik ISSN Eşleştirmesi
2020 yılı verileri
Journal of Pharmaceutical and Biomedical Analysis
Q1
SJR Quartile
0,777
SJR Skoru
154
H-Index
Kategoriler: Pharmaceutical Science (Q1) · Analytical Chemistry (Q2) · Clinical Biochemistry (Q2) · Drug Discovery (Q2) · Spectroscopy (Q2)
Alanlar: Biochemistry, Genetics and Molecular Biology · Chemistry · Pharmacology, Toxicology and Pharmaceutics
Ülke: Netherlands
· Elsevier B.V.
Bu bilgiler makale yılına göre Scimago veritabanından ISSN eşleştirmesiyle otomatik getirilmektedir.
Dergi sıralama verileri Scimago'nun ilgili yılı baz alınmaktadır.
Anahtar Kelimeler
YÖKSİS |
Bir kelimeye tıklayıp ilgili kaynaktaki yayınları görün.
Makale Bilgileri
Dergi
Journal of Pharmaceutical and Biomedical Analysis
ISSN
0731-7085
Yıl
2020
/ 2. ay
Cilt / Sayı
180
/ 4
Sayfalar
113056 – 113056
Makale Türü
Özgün Makale
Hakemlik
Hakemli
Endeks
SCI-Expanded
JCR Quartile
Q2
Yayın Dili
İngilizce
Kapsam
Uluslararası
Toplam Yazar
8 kişi
Erişim Türü
Elektronik
Alan
Sağlık Bilimleri Temel Alanı
Tıbbi Biyokimya
YÖKSİS Yazar Kaydı
Yazar Adı
Gharab Karam Mazin Kamil, ERYAVUZ ONMAZ DUYGU, Abusoglu Sedat, Aydin Memduha, Sivrikaya Abdullah, Tok Oguzhan, Abusoglu Gulsum, Unlu Ali
YÖKSİS ID
4431434